{"id":8532,"date":"2016-08-30T14:38:53","date_gmt":"2016-08-30T19:38:53","guid":{"rendered":"https:\/\/phrdev.pixelpro.website\/novedades-categoria\/colombia-80\/"},"modified":"2020-10-28T10:04:01","modified_gmt":"2020-10-28T15:04:01","slug":"colombia-80","status":"publish","type":"post","link":"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/","title":{"rendered":"COLOMBIA"},"content":{"rendered":"<p><strong>COLOMBIA<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>CLEAR RULES FOR PHARMACEUTICAL MARKETING AUTHORIZATIONS <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The Colombian Regulatory Authority (INVIMA), demands the submission of bioequivalence and bioavailability studies in order to grant marketing authorizations. Said studies seek to demonstrate the quality, efficacy and safety of one type of drug in comparison to another one containing the same principle and dose, and to analyze the drug&#8217;s capability to act in a particular time frame and site.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong> <\/strong><\/p>\n<p style=\"text-align: justify;\">Before the existence of INVIMA\u2019S Resolution No. 1124, all people or entities seeking to obtain a marketing authority for a drug, had to provide the bioequivalence and bioavailability report without the possibility of validating the studies already approved by foreign competent authorities. With today\u2019s regulation it is possible for applicants to use reports approved by foreign authorities in Colombia.<\/p>\n<p style=\"text-align: justify;\">The mentioned resolution applies to institutions that carry out bioavailability and bioequivalence studies, as well as to chemical synthesis products that require said studies (namely, those that contain at least one of the active ingredients included in the list of said resolution). Therefore, not all generic drugs must have the corresponding studies.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>CLEAR RULES FOR PHARMACEUTICAL MARKETING AUTHORIZATIONS<\/p>\n<p>The Colombian Regulatory Authority (INVIMA), demands the submission of bioequivalence and bioavailability studies in order to grant marketing authorizations. Said studies seek to demonstrate the quality, efficacy and safety of one type of drug in comparison to another one containing the same principle and dose, and to analyze the drug&#8217;s capability to act in a particular time frame and site.<\/p>\n","protected":false},"author":2,"featured_media":8339,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[146],"tags":[],"class_list":["post-8532","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-boletin-legal","areas-abogado-intellectual-property"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>COLOMBIA - PHR Legal | Posse Herrera Ruiz<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"COLOMBIA - PHR Legal | Posse Herrera Ruiz\" \/>\n<meta property=\"og:description\" content=\"CLEAR RULES FOR PHARMACEUTICAL MARKETING AUTHORIZATIONS  The Colombian Regulatory Authority (INVIMA), demands the submission of bioequivalence and bioavailability studies in order to grant marketing authorizations. Said studies seek to demonstrate the quality, efficacy and safety of one type of drug in comparison to another one containing the same principle and dose, and to analyze the drug&#039;s capability to act in a particular time frame and site.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/\" \/>\n<meta property=\"og:site_name\" content=\"PHR Legal | Posse Herrera Ruiz\" \/>\n<meta property=\"article:published_time\" content=\"2016-08-30T19:38:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-10-28T15:04:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/phrlegal.com\/wp-content\/uploads\/2020\/10\/IP-Destacada.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"690\" \/>\n\t<meta property=\"og:image:height\" content=\"440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Editor Pixelpro\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/\"},\"author\":{\"name\":\"Editor Pixelpro\",\"@id\":\"https:\/\/phrlegal.com\/en\/#\/schema\/person\/c1aec2a5e55d060bf5a5362878b7133c\"},\"headline\":\"COLOMBIA\",\"datePublished\":\"2016-08-30T19:38:53+00:00\",\"dateModified\":\"2020-10-28T15:04:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/\"},\"wordCount\":181,\"publisher\":{\"@id\":\"https:\/\/phrlegal.com\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/phrlegal.com\/wp-content\/uploads\/2020\/10\/IP-Destacada.jpg\",\"articleSection\":[\"Bolet\u00edn legal\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/\",\"url\":\"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/\",\"name\":\"COLOMBIA - PHR Legal | Posse Herrera Ruiz\",\"isPartOf\":{\"@id\":\"https:\/\/phrlegal.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/phrlegal.com\/wp-content\/uploads\/2020\/10\/IP-Destacada.jpg\",\"datePublished\":\"2016-08-30T19:38:53+00:00\",\"dateModified\":\"2020-10-28T15:04:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/#primaryimage\",\"url\":\"https:\/\/phrlegal.com\/wp-content\/uploads\/2020\/10\/IP-Destacada.jpg\",\"contentUrl\":\"https:\/\/phrlegal.com\/wp-content\/uploads\/2020\/10\/IP-Destacada.jpg\",\"width\":690,\"height\":440},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/phrlegal.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"COLOMBIA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/phrlegal.com\/en\/#website\",\"url\":\"https:\/\/phrlegal.com\/en\/\",\"name\":\"PHR Legal | Posse Herrera Ruiz\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/phrlegal.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/phrlegal.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/phrlegal.com\/en\/#organization\",\"name\":\"POSSE HERRERA RUIZ\",\"url\":\"https:\/\/phrlegal.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/phrlegal.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/phrlegal.com\/wp-content\/uploads\/2020\/07\/logo.svg\",\"contentUrl\":\"https:\/\/phrlegal.com\/wp-content\/uploads\/2020\/07\/logo.svg\",\"width\":1,\"height\":1,\"caption\":\"POSSE HERRERA RUIZ\"},\"image\":{\"@id\":\"https:\/\/phrlegal.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/phrlegal.com\/en\/#\/schema\/person\/c1aec2a5e55d060bf5a5362878b7133c\",\"name\":\"Editor Pixelpro\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/phrlegal.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/phrlegal.com\/wp-content\/litespeed\/avatar\/d2ace311142d851b7d46b774f2e23d25.jpg?ver=1774974510\",\"contentUrl\":\"https:\/\/phrlegal.com\/wp-content\/litespeed\/avatar\/d2ace311142d851b7d46b774f2e23d25.jpg?ver=1774974510\",\"caption\":\"Editor Pixelpro\"},\"sameAs\":[\"https:\/\/pixelpro.com.co\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"COLOMBIA - PHR Legal | Posse Herrera Ruiz","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/","og_locale":"en_US","og_type":"article","og_title":"COLOMBIA - PHR Legal | Posse Herrera Ruiz","og_description":"CLEAR RULES FOR PHARMACEUTICAL MARKETING AUTHORIZATIONS  The Colombian Regulatory Authority (INVIMA), demands the submission of bioequivalence and bioavailability studies in order to grant marketing authorizations. Said studies seek to demonstrate the quality, efficacy and safety of one type of drug in comparison to another one containing the same principle and dose, and to analyze the drug's capability to act in a particular time frame and site.","og_url":"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/","og_site_name":"PHR Legal | Posse Herrera Ruiz","article_published_time":"2016-08-30T19:38:53+00:00","article_modified_time":"2020-10-28T15:04:01+00:00","og_image":[{"width":690,"height":440,"url":"https:\/\/phrlegal.com\/wp-content\/uploads\/2020\/10\/IP-Destacada.jpg","type":"image\/jpeg"}],"author":"Editor Pixelpro","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/#article","isPartOf":{"@id":"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/"},"author":{"name":"Editor Pixelpro","@id":"https:\/\/phrlegal.com\/en\/#\/schema\/person\/c1aec2a5e55d060bf5a5362878b7133c"},"headline":"COLOMBIA","datePublished":"2016-08-30T19:38:53+00:00","dateModified":"2020-10-28T15:04:01+00:00","mainEntityOfPage":{"@id":"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/"},"wordCount":181,"publisher":{"@id":"https:\/\/phrlegal.com\/en\/#organization"},"image":{"@id":"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/#primaryimage"},"thumbnailUrl":"https:\/\/phrlegal.com\/wp-content\/uploads\/2020\/10\/IP-Destacada.jpg","articleSection":["Bolet\u00edn legal"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/","url":"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/","name":"COLOMBIA - PHR Legal | Posse Herrera Ruiz","isPartOf":{"@id":"https:\/\/phrlegal.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/#primaryimage"},"image":{"@id":"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/#primaryimage"},"thumbnailUrl":"https:\/\/phrlegal.com\/wp-content\/uploads\/2020\/10\/IP-Destacada.jpg","datePublished":"2016-08-30T19:38:53+00:00","dateModified":"2020-10-28T15:04:01+00:00","breadcrumb":{"@id":"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/#primaryimage","url":"https:\/\/phrlegal.com\/wp-content\/uploads\/2020\/10\/IP-Destacada.jpg","contentUrl":"https:\/\/phrlegal.com\/wp-content\/uploads\/2020\/10\/IP-Destacada.jpg","width":690,"height":440},{"@type":"BreadcrumbList","@id":"https:\/\/phrlegal.com\/en\/legal-bulletin\/colombia-80\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/phrlegal.com\/en\/"},{"@type":"ListItem","position":2,"name":"COLOMBIA"}]},{"@type":"WebSite","@id":"https:\/\/phrlegal.com\/en\/#website","url":"https:\/\/phrlegal.com\/en\/","name":"PHR Legal | Posse Herrera Ruiz","description":"","publisher":{"@id":"https:\/\/phrlegal.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/phrlegal.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/phrlegal.com\/en\/#organization","name":"POSSE HERRERA RUIZ","url":"https:\/\/phrlegal.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/phrlegal.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/phrlegal.com\/wp-content\/uploads\/2020\/07\/logo.svg","contentUrl":"https:\/\/phrlegal.com\/wp-content\/uploads\/2020\/07\/logo.svg","width":1,"height":1,"caption":"POSSE HERRERA RUIZ"},"image":{"@id":"https:\/\/phrlegal.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/phrlegal.com\/en\/#\/schema\/person\/c1aec2a5e55d060bf5a5362878b7133c","name":"Editor Pixelpro","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/phrlegal.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/phrlegal.com\/wp-content\/litespeed\/avatar\/d2ace311142d851b7d46b774f2e23d25.jpg?ver=1774974510","contentUrl":"https:\/\/phrlegal.com\/wp-content\/litespeed\/avatar\/d2ace311142d851b7d46b774f2e23d25.jpg?ver=1774974510","caption":"Editor Pixelpro"},"sameAs":["https:\/\/pixelpro.com.co\/"]}]}},"_links":{"self":[{"href":"https:\/\/phrlegal.com\/en\/wp-json\/wp\/v2\/posts\/8532","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/phrlegal.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/phrlegal.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/phrlegal.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/phrlegal.com\/en\/wp-json\/wp\/v2\/comments?post=8532"}],"version-history":[{"count":0,"href":"https:\/\/phrlegal.com\/en\/wp-json\/wp\/v2\/posts\/8532\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/phrlegal.com\/en\/wp-json\/wp\/v2\/media\/8339"}],"wp:attachment":[{"href":"https:\/\/phrlegal.com\/en\/wp-json\/wp\/v2\/media?parent=8532"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/phrlegal.com\/en\/wp-json\/wp\/v2\/categories?post=8532"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/phrlegal.com\/en\/wp-json\/wp\/v2\/tags?post=8532"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}